GlassScriptPhysician profile
Kavin Glen Hanzik
NPI 1952460750
$6,852.39
in general payments reported to CMS, 2019-2025
59 companies · $2,459 in 2025
The $2,459 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $88.24 · 2022: $1,395 · 2023: $1,475 · 2024: $1,436 · 2025: $2,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,985 · Education: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,984.87 |
| Education | $384.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,028.08 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $520.88 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $402.99 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $393.32 | 2022-2025 | Calquence, Enhertu, Imfinzi |
| Janssen Biotech, INC. | $347.39 | 2022-2025 | Rybrevant, Carvykti, Tecvayli |
| Takeda Pharmaceuticals U.S.A., INC. | $270.72 | 2022-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Abbvie INC. | $246.81 | 2022-2025 | |
| Gilead Sciences, INC. | $240.16 | 2022-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $229.96 | 2022-2025 | Opdivo, Opdualag |
| Astellas Pharma US INC | $226.06 | 2025 | Xtandi, Vyloy |
| Myriad Genetic Laboratories, INC. | $204.41 | 2021-2025 | Mychoice Cdx, Myrisk, Bracanalysis Cdx |
| Seagen INC. | $154.10 | 2022-2023 | Padcev, Adcetris |
| Incyte Corporation | $149.71 | 2022-2025 | Jakafi, Niktimvo, Monjuvi |
| Genzyme Corporation | $135.07 | 2022-2024 | |
| Sobi, INC | $130.29 | 2022-2024 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $122.31 | 2023-2025 | Ojjaara, Shingrix, Blenrep |
| Celgene Corporation | $108.50 | 2022-2025 | Pomalyst, Breyanzi |
| Pharmacosmos Therapeutics INC. | $107.56 | 2023-2025 | Monoferric |
| Karyopharm Therapeutics INC. | $100.60 | 2022-2024 | Xpovio |
| Bayer Healthcare Pharmaceuticals INC. | $97.60 | 2022-2025 | |
| Daiichi Sankyo INC. | $97.00 | 2022-2025 | Datroway, Enhertu |
| Aveo Pharmaceuticals, INC. | $91.70 | 2022-2024 | Fotivda |
| Puma Biotechnology, INC. | $87.11 | 2022-2025 | Nerlynx |
| Emd Serono, INC. | $82.44 | 2024-2025 | |
| Mirati Therapeutics, INC. | $72.29 | 2023 | Krazati |
| Sumitomo Pharma America, INC. | $71.15 | 2023-2025 | Orgovyx |
| Stemline Therapeutics INC. | $67.64 | 2024-2025 | Orserdu |
| Eisai INC. | $64.49 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $60.58 | 2024 | Empaveli |
| Pharmacyclics LLC, An Abbvie Company | $60.52 | 2022-2023 | Imbruvica |
| Pharmaessentia USA Corporation | $58.28 | 2024-2025 | Besremi |
| Morphosys, US INC. | $52.09 | 2022 | |
| Array Biopharma INC | $51.29 | 2022-2025 | Mektovi, Braftovi, Tukysa |
| Beigene USA, INC. | $48.07 | 2022 | |
| Pharming Healthcare, INC. | $45.25 | 2022-2025 | Ruconest |
| Amgen INC. | $44.01 | 2022-2023 | Kyprolis, Blincyto |
| Recordati_rare_diseases_inc. | $43.54 | 2025 | Enjaymo |
| Ipsen Biopharmaceuticals, INC | $41.89 | 2025 | Onivyde |
| Exelixis INC. | $37.21 | 2024-2025 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $34.90 | 2022-2025 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $34.37 | 2022-2024 | Libtayo |
| Syndax Pharmaceuticals, INC. | $31.78 | 2025 | |
| Genentech USA, INC. | $30.13 | 2022 | |
| Deciphera Pharmaceuticals INC. | $29.23 | 2025 | Qinlock, Romvimza |
| Rigel Pharmaceuticals, INC. | $26.51 | 2024 | Tavalisse, Rezlidhia |
| Lilly USA, LLC | $24.51 | 2022 | |
| Genmab U.S., INC. | $22.67 | 2025 | Epkinly |
| Adc Therapeutics America, INC. | $22.39 | 2023 | |
| Global Blood Therapeutics, INC. | $22.19 | 2022 | |
| Pharmaand Gmbh | $20.74 | 2025 | Rubraca |
| Tolmar, INC. | $20.74 | 2025 | Rubraca, Eligard |
| Caris Mpi, INC. | $19.57 | 2025 | Mi Cancer Seek |
| Mylan Institutional INC. | $19.45 | 2023 | Ogivri, Fulphila |
| Tactile Systems Technology INC | $19.19 | 2022 | |
| Taiho Oncology, INC. | $18.41 | 2022 | |
| Agios Pharmaceuticals, INC. | $17.56 | 2025 | Pyrukynd |
| Springworks Therapeutics, INC. | $16.27 | 2024 | Ogsiveo |
| Cti Biopharma Corp. | $14.46 | 2023 | Vonjo |
| Sun Pharmaceutical Industries INC. | $14.25 | 2023 | Odomzo, Yonsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kavin Hanzik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.